Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering
NEW YORK, April 28 —
Oruka Therapeutics (ORKA) surged over 21% to a record high, then immediately filed a $500M stock offering to cash in.
- ORKA-001 Phase IIa trial hit 64% skin clearance in plaque psoriasis patients
- Company filed a $500M underwritten offering with a $75M greenshoe option, up to $575M total
- Guggenheim set a $200 price target; BTIG raised its target by 94%
What Actually Happened
Oruka's lead drug, ORKA-001, is a half-life extended IL-23p19 inhibitor designed for once-yearly dosing. That dosing schedule is the entire investment case. The IL-23 class already dominates psoriasis treatment — AbbVie's Skyrizi alone did over $10bn in 2025 sales. But Skyrizi and its competitors require injections every 8 to 12 weeks. Once a year would be a step change in patient convenience.
The 64% skin clearance from Phase IIa is the first clinical proof that extended dosing might work. Analysts moved quickly. Guggenheim slapped a $200 price target on a $76 stock. BTIG nearly doubled its target. Wall Street read this as best-in-class data, and the stock priced it in same-day.
Then came the capital raise. Within days of the record high, Oruka filed a $500M underwritten public offering with a $75M greenshoe — up to $575M total. That is an enormous raise for a company with no revenue and a negative forward P/E of -28.7x. Management saw the window and jumped through it.
The Catch
Phase IIa is early. Critically early. These trials use small patient groups to show a signal, not prove efficacy at the level regulators demand. The 64% clearance number faces much tougher scrutiny in Phase IIb/III. Larger patient populations and longer follow-up periods tend to humble early results. Plenty of promising Phase IIa psoriasis drugs have stumbled later.
The $575M raise also dilutes existing shareholders at what could be peak enthusiasm. If you bought ORKA before the data and are sitting on a 21% gain, consider what management just signaled: they think the stock is expensive enough to sell a lot of it. Weigh that against the analyst upgrades.
Bottom Line
The science is genuinely interesting. Once-yearly dosing in a $30bn+ psoriasis market would be a category-defining product — if it holds up. But "if it holds up" is doing a lot of work in that sentence. The stock is priced for a future still two or three clinical readouts away. The company just diluted shareholders to fund the path there.
The next catalysts: Phase IIb/III initiation timeline and durability data from extended follow-up. Those will determine whether ORKA-001 is a real threat to Skyrizi or a clean Phase IIa story that faded in later trials.
Want a full financial breakdown on Oruka Therapeutics? Generate a free ORKA report on Basis Report.
Basis Report does not hold positions in securities discussed. This is not investment advice.